Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-resistant/-intolerant chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with imatinib-resistant/-intolerant CML in chronic phase (CML-CP) received dasatinib 100 mg once daily, 50 mg twice daily,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Shah, Neil P., Guilhot, François, Cortes, Jorge E., Schiffer, Charles A., le Coutre, Philipp, Brümmendorf, Tim H., Kantarjian, Hagop M., Hochhaus, Andreas, Rousselot, Philippe, Mohamed, Hesham, Healey, Diane, Cunningham, Michael, Saglio, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915794/
https://ncbi.nlm.nih.gov/pubmed/24569263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-532341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados